FacebookTwitterGoogle+RedditEmail

Marijuana Might Really Make You Cool

Marijuana use may confer health benefits by lowering overall body temperature, according to Tod Mikuriya, MD. It has been observed by his office staff -and confirmed anecdotally by colleagues- that people seeking physician approval to medicate with cannabis usually register body temperatures markedly below 98.6. Just as lower calorie consumption is associated with greater longevity, lower temperature could confer an advantage by slowing down metabolism! (Sometimes “great ideas” are simple and obvious. For example, all history is the story of class struggle, and, in addition to the thoughts we’re aware of, we have unconscious thoughts that can be glimpsed in dreams.) Mikuriya writes in the new O’Shaughnessy’s:

Hypothermia in the mouse is one of the “classic tetrad” of symptoms indicating activation of the cannabinoid system. The genesis of hypothermia requires further study. The Indian Hemp Drugs Commission observed that one of the reputed benefits was to help laborers tolerate the heat. Cannabis was described as used to cool the passions -in contrast with alcohol, which heated them.

Clinically, cannabis appears to actually lower temperature and a couple of patients have described a sense of cold with transient shivering. The question could be answered readily by comparing temperatures of persons who have THC metabolites in their urine and people who don’t. If there turns out to be a significantly lower temperature in the cannabis-using population, one might posit a slower metabolic rate which, over time, might have implications for longevity. Temperature has a significant effect on metabolic rate. We have to understand the mechanism of hypothermogenesis.

If there is a hypothermia, what influence is there on the HPA (Hypothalamus Pituitary Adrenal networks) and all of the interactions affecting levels of circulating cortisol and epinephrine, etc.? With management of diabetes, cannabis decreases blood sugar by diminishing gluconeogenesis, which plays out in decreased insulin requirement and improved stability.

This hypothermogenic effect appears to be dose-related and could contribute to a neuroprotective effect after trauma. The optimum delivery method will require study. Hopefully, we will see a vaporizer on ambulances for treatment of head injury and seizures, and at the bedside of pre- and post-neurosurgery patients.

In addition to external cooling, cannabis quiets the irritable CNS. A combination of inhaled and oral cannabis would be appropriate for acute CNS trauma from internal or external etiology. I predict this will become accepted and mainstream in the future.

Raphael Mechoulam’s lab published a paper in 2003 showing that hypothermia appears to be an important factor as to why the synthetic THC analog HU-210 was protective in an animal model of stroke. [Leker, R.R., Gai, N., Mechoulam, R. and Ovadia, H. (2003) Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34, 2000-2006]… If a patient presents to an ER with a stroke, the first thing they will do is put the patient’s head in a cooler and pump them full of antioxidants (vitamin E).

There’s many a pothead thinks their drug of choice makes them cooler than the general population. Wait till they find out how much cooler! O’Shaughnessy’s is the journal of sorts that I produce for California’s small but growing group of pro-cannabis doctors. It is not available by subscription, but a contribution of any amount to the CCRMG (California Cannabis Research Medical Group) will get you on the mailing list for Fall ’05 and future issues. The CCRMG is a 501(c)3 non-profit; contributions are tax deductible. It was founded in 1999 by Mikuriya, whose pioneering clinical research has been rewarded by the Medical Board of California with a $75,000 fine (to pay for the cost of his own prosecution; the liberal equivalent of being made to dig your own grave). The CCRMG is not supported by a generous grant from MPP, Green Aid, DPA and other reform bureaucracies. It is BY FAR the best way to support the medical marijuana movement (as opposed to the medical marijuana industry, which does not really need external support). Please send what you can to CCRMG, po box 9143, Berkeley CA 94709 But wait, there’s more! If you order now, you’ll also receive a never-before published transcript of the 1937 Congressional Hearing that led to the Prohibition of Marijuana, with commentary by your correspondent.

Two more nuggets from the new O’Shaughnessy’s follow.

Enter THC-V (tetrohydrocannabivarin)

The big news at this year’s meeting of the International Cannabinoid Research Society, as reported on Counterpunch.org, the Anderson Valley Advertiser, and almost nowhere else, alas, was the conclusion by Donald Tashkin, MD, and colleagues at UCLA that marijuana smoking -“even heavy, longterm use”- does not cause cancer of the lung, upper airways, or esophagus. Among the other talks of apparent significance was one by Roger Pertwee, MD, of the University of Aberdeen, who described experiments using a cannabis strain bred by G.W. Pharmaceuticals to be high in THC-V (tetrohydrocannabivarin). It turns out that THCV strongly antagonizes anandamide -one of the body’s own cannabinoids- while hardly antagonizing the plant cannabinoid THC! It’s as if the cannabis plant contains and makes available to the body a choice of drugs and the body uses those it needs to achieve a balanced state (homeostasis). If the body is producing endocannabinoids in excess, it can use the plant cannabinoid THC-V to achieve homeostasis. If the endocannabinoid system needs a boost, the THC provides it (while the THC-V shuts down the endocannabinoid system, giving it a rest as it were). The key to relief, apparently, is not high cannabinoid levels but proper gradients. Geoffrey Guy, MD, expounded in an interview: “It’s as if the plant contains a first-aid kit giving the body everything it needs to get bettter, and the body decides which components to employ… The endocannibnoid system begins to kick in in abnormality, in pathology. Perhaps it kicks in whether the pathology is an increase in something or a decrease in something. What it’s trying to do is get whatever that abnormality is back to homeostasis.

“The antagonist may be working to restore function back to the center, and the agonist might be working to restore function back to the center, and once they’ve achieved the norm, they don’t go any further. The endocannabnioid system is the supeme modulator. Its job is done once you’re back to the norm. Most endocannabinoid modulators simply won’t drive the physiology or biochemistry whatever they’re controlling past the norm to a detrimental effect.”

Which might explain the apparent benignity of Rimonabant, a drug that works by blocking the CB1 receptor system. Rimonabant is being tested by Sanofi-Aventis for weight loss and smoking cessation. Originally known as SR-141716, it was developed in the early 1990s as an antagonist drug for use by researchers. At the 2004 ICRS meeting, Sanofi researchers described favorable results from clinical trials of Rimonabant as a diet drug. They informally predicted regulatory approval in Europe and the U.S. within a year. Some observers warned that blocking the CB1 receptor system could result in unforeseen longterm side effects and noted that at least one MS patient had experienced an exacerbation after taking Rimonabant.

Although regulatory approval has not yet been granted, Sanofi reported good news at the 2005 meeting regarding side-effects: no more MS cases in a smoking-cessation study study involving more than 1,000 patients worldwide. “Both the 5mg and 20mg doses continued to show efficacy in the maintenance of abstinence from smoking,” reported Gerard Le Fur. “The 20mg dose also demonstrated efficacy in the reduction of weight gain as well as significantly increasing the HDL-Cholesterol levels.”

A Sanofi team also reported favorable results from studies using Rimonabant to treat various rodent models of “metabolic syndrome” -obesity-related high blood pressure, high insulin levels, excessive triglycerides and “bad” cholesterol and other problems increasing the risk of diabetes, heart attack and stroke. There is growing acceptance of the notion that the body can adjust to even a heavy blockade of the CB1 system. Perhaps when the CB1 receptor is blocked, the endocannabinoids are redirected to other targets. At times the layman is struck by how rudimentary the biochemists’ understanding of the body’s mechanism of action really is.

“We’re on plateau one or two and the answer is on plateau 12,” said Guy. “We could spend the next 30 years on receptors and still not fully understand them. When we talk about receptors and agonists and antagonists we should be talking in the same breath about functionality -real functionality, not models in non-pathological situations. We need an understanding of the clinical outcome.”

Americans who follow the medical marijuana movement may recall hearing of THC-V in the late 1990s, when the feds were trying to imprison would-be researcher Todd McCormick for violating a court order by ingesting marijuana (as opposed to Marinol). McCormick’s criminality was proven by a pee test, specially designed by pharmacologist Mahmoud El Sohly to distinguish legal ingestion of pure, synthetic THC (Marinol) from illegal ingestion of herbal THC with its modulating compounds (THC-V et al). The THC-V test cost something like $15,000 to administer. The contrasting uses to which THC-V has been put by European and U.S. scientists says it all. Theirs are working towards understanding the plant and producing effective herbal medicines. Ours are working to develop keener tools for law-enforcement and strong, “pure” synthetics. Now let us contrast the Dutch and U.S. approaches towards coastline protection…

 

Goldberg’s Monkeys Bat Last

A researcher named Steven Goldberg maintains a colony of monkeys in Baltimore, Maryland that have been trained to self-administer THC (by injection). At this year’s ICRS meeting Goldberg presented a poster co-authored by Zuzana Justinova on “The Abuse Potential of the Endocannbinoid Transport Inhibitor AM404: Self-Administration by Squirrel Monkeys.”

AM404 is one of the many compounds that corporate- and government-funded scientists are developing in hopes of achieving higher cannabinoid levels by indirect means. Goldberg’s monkeys liked AM404 enough to self-administer it, which means, in NIDA’s terms, that AM404 is a drug with potential for abuse. So, after all their efforts to create an alternative to the illegal herb, the drug companies will have to run their products by Goldberg’s monkeys!

The Goldberg-Justinova poster concluded “AM404 functioned as an effective reinforcer (comparable to THC, anadamide and cocaine under identical conditions) in non-human primates under a fixed-ratio schedule of drug injection. Our findings suggest that medications which promote the actions of endocannabinoids throughout the brain by inhibiting their membrane transport have a potential for abuse. It remains to be seen whether medications such as FAAH inhibitors, which augment CB1 signaling only in certain regions of the nervous system, would be self-administered in a similar manner.”

I’d always heard that monkeys couldn’t be trained to self-administer THC, and mentioned this to Goldberg. Other researchers had used “Old World monkeys,” he said, sounding somewhat disdainful, whereas he used squirrel monkeys from South America (as if our New World monkeys are inherently hipper). But the real key to his success, he added, was the very low doses with which he rewarded the monkeys. This made sense -most of the primates I know prefer a slight alteration of mood to getting knocked-out-loaded. It also resonated with a talk on neuroprotection by Italian investigators in which they found that a synthetic cannabinoid was beneficial only at the lowest concentrations tested, and detrimental at high concentrations. When the name of the game is The Cannabinoid System, less can be more.

FRED GARDNER can be reached at: fred@plebesite.com

 

 

 

 

 

 

More articles by:

Fred Gardner is the managing editor of O’Shaughnessy’s. He can be reached at fred@plebesite.com

February 19, 2019
Richard Falk – Daniel Falcone
Troublesome Possibilities: The Left and Tulsi Gabbard
Patrick Cockburn
She Didn’t Start the Fire: Why Attack the ISIS Bride?
Evaggelos Vallianatos
Literature and Theater During War: Why Euripides Still Matters
Maximilian Werner
The Night of Terror: Wyoming Game and Fish’s Latest Attempt to Close the Book on the Mark Uptain Tragedy
Conn Hallinan
Erdogan is Destined for Another Rebuke in Turkey
Nyla Ali Khan
Politics of Jammu and Kashmir: The Only Viable Way is Forward
Mark Ashwill
On the Outside Looking In: an American in Vietnam
Joyce Nelson
Sir Richard Branson’s Venezuelan-Border PR Stunt
Ron Jacobs
Day of Remembrance and the Music of Anthony Brown        
Cesar Chelala
Women’s Critical Role in Saving the Environment
February 18, 2019
Paul Street
31 Actual National Emergencies
Robert Fisk
What Happened to the Remains of Khashoggi’s Predecessor?
David Mattson
When Grizzly Bears Go Bad: Constructions of Victimhood and Blame
Julian Vigo
USMCA’s Outsourcing of Free Speech to Big Tech
George Wuerthner
How the BLM Serves the West’s Welfare Ranchers
Christopher Fons
The Crimes of Elliot Abrams
Thomas Knapp
The First Rule of AIPAC Is: You Do Not Talk about AIPAC
Mitchel Cohen
A Tale of Two Citations: Rachel Carson’s “Silent Spring” and Michael Harrington’s “The Other America”
Jake Johnston
Haiti and the Collapse of a Political and Economic System
Dave Lindorff
It’s Not Just Trump and the Republicans
Laura Flanders
An End to Amazon’s Two-Bit Romance. No Low-Rent Rendezvous.
Patrick Walker
Venezuelan Coup Democrats Vomit on Green New Deal
Natalie Dowzicky
The Millennial Generation Will Tear Down Trump’s Wall
Nick Licata
Of Stress and Inequality
Joseph G. Ramsey
Waking Up on President’s Day During the Reign of Donald Trump
Elliot Sperber
Greater Than Food
Weekend Edition
February 15, 2019
Friday - Sunday
Matthew Hoh
Time for Peace in Afghanistan and an End to the Lies
Chris Floyd
Pence and the Benjamins: An Eternity of Anti-Semitism
Rob Urie
The Green New Deal, Capitalism and the State
Jim Kavanagh
The Siege of Venezuela and the Travails of Empire
Paul Street
Someone Needs to Teach These As$#oles a Lesson
Andrew Levine
World Historical Donald: Unwitting and Unwilling Author of The Green New Deal
Jeffrey St. Clair
Roaming Charges: Third Rail-Roaded
Eric Draitser
Impacts of Exploding US Oil Production on Climate and Foreign Policy
Ron Jacobs
Maduro, Guaidó and American Exceptionalism
John Laforge
Nuclear Power Can’t Survive, Much Less Slow Climate Disruption
Joyce Nelson
Venezuela & The Mighty Wurlitzer
Jonathan Cook
In Hebron, Israel Removes the Last Restraint on Its Settlers’ Reign of Terror
Ramzy Baroud
Enough Western Meddling and Interventions: Let the Venezuelan People Decide
Robert Fantina
Congress, Israel and the Politics of “Righteous Indignation”
Dave Lindorff
Using Students, Teachers, Journalists and other Professionals as Spies Puts Everyone in Jeopardy
Kathy Kelly
What it Really Takes to Secure Peace in Afghanistan
Brian Cloughley
In Libya, “We Came, We Saw, He Died.” Now, Maduro?
Nicky Reid
The Councils Before Maduro!
Gary Leupp
“It’s All About the Benjamins, Baby”
FacebookTwitterGoogle+RedditEmail